Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
- 142 Downloads
Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer.
Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts. The 750 mg QD start dose was a phase 2 dose determined for men with castration-resistant prostate cancer in (Shore et al. J Clin Oncol 34, 2016). Enrollment at lower doses was initiated in the presence of dose-limiting toxicities (DLTs). The primary objective of this study was to determine seviteronel safety, tolerability, and MTD. The secondary objectives included description of its PK in women and its initial activity, including clinical benefit rate at 4 (CBR16) and 6 months (CBR24).
Nineteen women were enrolled. A majority of adverse events (AEs) were Grade (Gr) 1/2, independent of relationship; the most common were tremor (42%), nausea (42%), vomiting (37%), and fatigue (37%). Four Gr 3/4 AEs (anemia, delirium, mental status change, and confusional state) deemed possibly related to seviteronel occurred in four subjects. DLTs were observed at 750 mg (Gr 3 confusional state with paranoia) and 600 mg (Gr 3 mental status change and Gr 3 delirium) QD, with none at 450 mg QD. The recommended phase 2 dose (RP2D) was 450 mg QD, and at the RP2D, 4 of 7 subjects reached at least CBR16 (2 TNBC subjects and 2 ER+ subjects achieved CBR16 and CBR24, respectively); no objective tumor responses were reported.
Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D.
KeywordsCYP17 lyase Androgen receptor Breast cancer Seviteronel
This study was funded by Innocrin Pharmaceuticals. E.S.B-B and J.R.E are compensated employees of Innocrin Pharmaceuticals. T.A.T. receives compensation as a Steering Committee member for Innocrin Pharmaceuticals.
Compliance with ethical standards
Conflict of interest
All other authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Shore ND, Gupta S, Fleming MT, Berry WR, Zhang J, Kurman MR, Eisner JR, Moore WR (2016) Once-nightly (QD) dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464 in patients with CRPC. J Clin Oncol 34 (2): [2016 Genitourinary Cancers Symposium])Google Scholar
- 2.Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093 CrossRefPubMedGoogle Scholar
- 3.Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (19):10869–10874. https://doi.org/10.1073/pnas.19136709898/19/10869 CrossRefPubMedGoogle Scholar
- 4.Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (14):8418–8423. https://doi.org/10.1073/pnas.09326921000932692100 CrossRefPubMedGoogle Scholar
- 5.Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18(2):112–118PubMedGoogle Scholar
- 8.Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660–4671. https://doi.org/10.1038/sj.onc.1208561 CrossRefPubMedGoogle Scholar
- 9.Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28):3994–4008. doi:1209415 [pii] https://doi.org/10.1038/sj.onc.1209415 CrossRefPubMedGoogle Scholar
- 10.Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/JCI45014 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, Translational Breast Cancer Research C (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 19(19):5505–5512. https://doi.org/10.1158/1078-0432.CCR-12-3327 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L’Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Goncalves A (2016) A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12 – 1). Ann Oncol 27(5):812–818. https://doi.org/10.1093/annonc/mdw067 CrossRefPubMedGoogle Scholar
- 13.Traina TA, Miller K, Yardley DA, O’Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME, Schmid P, Gianni L, Garcia-Estevez L, Nanda R, Ademuyiwa FO, Chan S, Steinberg JL, Blaney ME, Tudor IC, Uppal H, Peterson AC, Hudis CA (2015) Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR + triple-negative breast cancer (TNBC). ASCO Meet Abstr 33 (15_suppl):1003Google Scholar
- 14.De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Ando S, Fuqua SA (2010) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121(1):1–11. https://doi.org/10.1007/s10549-009-0436-8 CrossRefPubMedGoogle Scholar
- 15.Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA (2015) Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Breast Cancer Res Treat 154(2):225–237. https://doi.org/10.1007/s10549-015-3609-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16(1):R7. https://doi.org/10.1186/bcr3599 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Rechoum Y, Iacopetta D, Barone I, Rovito D, Ando S, Weigel N, Fuqua SAW (2013) Collaboration of AR and ERα in conferring resistance to an aromatase inhibitor. ASCO Meet Abstr 31:579Google Scholar
- 19.Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP (2017) Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest 127(6):2326–2338. https://doi.org/10.1172/JCI87328 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Ellison SJNJ., Wardell S, Eisner JR, Hoekstra WJ, Stagg DB, Alley HM, Moore WR, McDonnell DP (2016) Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo. [abstract]. Cancer Res 76 P3–14CrossRefGoogle Scholar
- 21.O’Shaughnessy J, Campone M, Brain E, Neven P, Hayes D, Bondarenko I, Griffin TW, Martin J, De Porre P, Kheoh T, Yu MK, Peng W, Johnston S (2016) Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol 27(1):106–113. https://doi.org/10.1093/annonc/mdv487 CrossRefPubMedGoogle Scholar
- 22.Martin RM, Lin CJ, Costa EM, de Oliveira ML, Carrilho A, Villar H, Longui CA, Mendonca BB (2003) P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J Clin Endocrinol Metab 88(12):5739–5746. https://doi.org/10.1210/jc.2003-030988 CrossRefPubMedGoogle Scholar
- 24.Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97(2):507–516. https://doi.org/10.1210/jc.2011-2189 CrossRefPubMedGoogle Scholar
- 25.de Bono J, Pezaro CJ, Gillessen S, Shore ND, Nordquist LT, Efstathiou E, Araujo JC, Berry WR, Liu G, Vogelzang NJ, Omlin AG, Schotzinger RJ, Eisner JR, Moore WR (2015) The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC. J Clin Oncol 33 ((suppl 7)):abstr 187Google Scholar
- 27.Longo DL FA, Kasper DL, Hauser SL, Jameson J, Loscalzo J (eds) (2012) Harrison’s principles of internal Medicine. 18 edn. McGraw-Hill, New YorkGoogle Scholar
- 30.Li W, O’Shaughnessy J, Hayes D, Campone M, Bondarenko I, Zbarskaya I, Brain E, Stenina M, Ivanova O, Graas MP, Neven P, Ricci D, Griffin T, Kheoh T, Yu M, Gormley M, Martin J, Schaffer M, Zelinsky K, De Porre P, Johnston SR (2016) Biomarker associations with efficacy of abiraterone acetate and exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22(24):6002–6009. https://doi.org/10.1158/1078-0432.CCR-15-2452 CrossRefPubMedGoogle Scholar
- 31.Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA (2017) A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res 23(15):4046–4054. https://doi.org/10.1158/1078-0432.CCR-16-2339 CrossRefPubMedGoogle Scholar
- 32.Eisner J, Abbott DH, Bird IM, Rafferty SW, Moore WR, Schotzinger RJ (2012) Assessment of steroid hormones upstream of P450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA). In: The Endocrine Society’s 94th Annual Meeting and Expo:abstr SAT-266Google Scholar
- 33.Ng CHMMI., Rea D et al. Phase I/II study of abiraterone acetate (AA) in estrogen receptor (ER) or androgen receptor (AR) positive metastatic breast cancer (MBC). European Society for Medical Oncology Congress, Vienna, September 28–October 2 2012Google Scholar
- 34.Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653 CrossRefPubMedGoogle Scholar
- 36.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709 CrossRefPubMedGoogle Scholar
- 37.Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol:JCO2017737585. https://doi.org/10.1200/JCO.2017.73.7585 Google Scholar
- 38.Gordon MA, D’Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK (2017) Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Mol Cancer Ther 16(7):1389–1400. https://doi.org/10.1158/1535-7163.MCT-17-0111 CrossRefPubMedPubMedCentralGoogle Scholar